Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.111 CHF
−217.56 M CHF
24.63 M CHF
54.63 M
About uniQure N.V.
Sector
Industry
CEO
Matthew C. Kapusta
Website
Headquarters
Amsterdam
Founded
2012
ISIN
NL0010696654
FIGI
BBG00LVGHR41
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UQ1 is 48.678 CHF — it has decreased by −6.70% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange uniQure N.V. stocks are traded under the ticker UQ1.
We've gathered analysts' opinions on uniQure N.V. future price: according to them, UQ1 price has a max estimate of 87.87 CHF and a min estimate of 44.73 CHF. Watch UQ1 chart and read a more detailed uniQure N.V. stock forecast: see what analysts think of uniQure N.V. and suggest that you do with its stocks.
UQ1 stock is 7.18% volatile and has beta coefficient of 0.76. Track uniQure N.V. stock price on the chart and check out the list of the most volatile stocks — is uniQure N.V. there?
Today uniQure N.V. has the market capitalization of 3.35 B, it has increased by 7.82% over the last week.
Yes, you can track uniQure N.V. financials in yearly and quarterly reports right on TradingView.
uniQure N.V. is going to release the next earnings report on Nov 3, 2025. Keep track of upcoming events with our Earnings Calendar.
UQ1 earnings for the last quarter are −0.55 CHF per share, whereas the estimation was −0.71 CHF resulting in a 22.89% surprise. The estimated earnings for the next quarter are −0.72 CHF per share. See more details about uniQure N.V. earnings.
uniQure N.V. revenue for the last quarter amounts to 4.17 M CHF, despite the estimated figure of 4.28 M CHF. In the next quarter, revenue is expected to reach 4.23 M CHF.
UQ1 net income for the last quarter is −29.93 M CHF, while the quarter before that showed −38.63 M CHF of net income which accounts for 22.53% change. Track more uniQure N.V. financial stats to get the full picture.
No, UQ1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2025, the company has 209 employees. See our rating of the largest employees — is uniQure N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. uniQure N.V. EBITDA is −130.50 M CHF, and current EBITDA margin is −632.89%. See more stats in uniQure N.V. financial statements.
Like other stocks, UQ1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade uniQure N.V. stock right from TradingView charts — choose your broker and connect to your account.